Does Testosterone Help an Enlarged Prostate?

Testosterone replacement does not appear to worsen an enlarged prostate and, in some men with low testosterone, may modestly improve urinary symptoms. This runs counter to a belief that persisted for decades in medicine, one that traced back to a single patient studied in 1941. The relationship between testosterone and the prostate turns out to be far more nuanced than the old “more testosterone equals more prostate growth” equation, and the latest large-scale trial data suggest that the fear was overblown.

Where the Fear Originated

The idea that testosterone fuels prostate problems goes back to work by Charles Huggins and Clarence Hodges in 1941. They showed that dramatically lowering testosterone through castration or estrogen treatment caused metastatic prostate cancer to regress, and that giving testosterone back made it grow again. This became the foundation of androgen-deprivation therapy, which remains a cornerstone of advanced prostate cancer treatment today. What often gets left out: the conclusion that testosterone administration caused cancer growth was based on results from a single patient.¹ From that single case, an entire generation of physicians absorbed the notion that testosterone was dangerous for the prostate across the board, whether you had cancer or just an enlarged gland.

DHT Is the Real Driver of Prostate Growth

The prostate doesn’t respond to testosterone directly so much as it responds to dihydrotestosterone, or DHT. Testosterone gets converted into DHT by an enzyme called 5-alpha reductase, and DHT binds to androgen receptors in the prostate far more potently. It is DHT that causes pathologic prostate growth in adulthood, even though it plays a normal role during prostate development earlier in life.² This distinction matters because drugs that block the conversion of testosterone to DHT (5-alpha reductase inhibitors like finasteride and dutasteride) can shrink the prostate, improve symptoms, and reduce the risk of acute urinary retention and surgery, without eliminating testosterone itself.³

There is also an aging component that complicates things. As men get older, DHT levels within the prostate tissue can actually accumulate alongside rising estrogen levels, creating a dramatic shift in the estrogen-to-androgen ratio, particularly in the connective tissue of the prostate. That hormonal rebalancing tracks closely with BPH development.⁴ So the story is not simply “androgens go up, prostate grows.” It is about the local hormonal environment inside the prostate shifting with age, and circulating testosterone levels in the blood are a poor proxy for what is happening at the tissue level.

Why Adding More Testosterone Doesn’t Keep Growing the Prostate

The saturation model, proposed by Abraham Morgentaler, explains the apparent paradox. Prostate tissue is highly sensitive to androgen levels when those levels are very low, as after castration. But once androgen receptor binding in the prostate reaches its maximum, which happens at serum testosterone concentrations well below the normal physiologic range, additional testosterone produces little further effect on prostate growth.⁵ Think of it like watering a sponge: the first cup of water gets absorbed readily, but once the sponge is saturated, pouring more water on top doesn’t change much.

This explains why castration (dropping testosterone near zero) shrinks the prostate so dramatically, while raising testosterone from low-normal to high-normal in a man already producing some testosterone barely moves the needle. The prostate’s androgen receptors are already occupied at modest testosterone levels. Going from zero to some is a huge change; going from some to more is not.

What the Clinical Evidence Shows

Several lines of evidence support the idea that testosterone therapy does not meaningfully worsen prostate size or urinary symptoms. In a study comparing testosterone-treated hypogonadal men, untreated hypogonadal men, and normal controls, prostate size in the treated group averaged about 21 cubic centimeters, virtually identical to the roughly 23 cubic centimeters seen in normal men. Untreated hypogonadal men had significantly smaller prostates (around 12 cubic centimeters), and their PSA levels were also lower. But the key finding was that bringing testosterone-deficient men up to normal levels gave them normal-sized prostates, not oversized ones.⁶

In healthy young men given exogenous testosterone at various doses, there was no significant change in prostate volume or serum PSA levels at any dose.⁷ That result aligns with the saturation model: men who already have normal testosterone levels see essentially no prostate response from additional testosterone.

The broader clinical picture tells a similar story. A meta-analysis of 14 clinical trials found no meaningful difference in urinary symptom scores between men receiving testosterone therapy and those on placebo. That held true regardless of the type of testosterone used, the degree of testosterone change achieved, or PSA levels.⁸ A separate systematic review found that men who started with mild urinary symptoms either saw no change or actually improved after testosterone treatment. Men with metabolic syndrome showed uniform improvement.⁹

The TRAVERSE Trial and Large-Scale Safety Data

The most definitive safety data come from the TRAVERSE trial, the largest randomized controlled trial of testosterone therapy to date. Over more than 14,000 person-years of follow-up, the rates of high-grade prostate cancer, any prostate cancer, acute urinary retention, invasive surgical procedures, prostate biopsy, and new drug treatment for BPH did not differ significantly between the testosterone and placebo groups.¹⁰ There was a small but statistically significant increase in PSA levels in the testosterone group during the first year of treatment, but after that first year the rate of PSA change was similar in both groups.¹¹ The urinary symptom scores also did not differ between testosterone and placebo.

A synthesis of data from the TRAVERSE trial and the TTrials confirmed that prostate-related events were comparable between groups.¹² The early PSA bump during the first year still warrants monitoring, but it does not translate into more cancer diagnoses or more urinary obstruction down the line.

Low Testosterone, Inflammation, and Metabolic Syndrome

One of the more counterintuitive findings in this field is that low testosterone may actually be worse for the prostate than normal testosterone. Metabolic syndrome, which includes obesity, insulin resistance, and dyslipidemia, is closely linked to both low testosterone and the development of BPH with lower urinary tract symptoms.¹³ Mounting evidence suggests that low testosterone and elevated estrogen can trigger prostate inflammation through metabolic pathways.¹⁴

A randomized trial looking at prostate tissue from men with testosterone deficiency found markedly increased inflammatory and metabolic markers compared to men with normal testosterone. When the testosterone-deficient men received testosterone therapy, those inflammatory markers dropped back down to levels comparable with the normal-testosterone group.¹⁵ Prostate inflammation is increasingly recognized as a contributor to BPH symptoms and progression, so reducing that inflammation through testosterone replacement could be one mechanism behind the symptom improvements seen in some clinical trials.

Epidemiological data point in the same direction. In a large cohort from the Prostate Cancer Prevention Trial, men in the highest quartile of serum testosterone had about a third lower odds of developing BPH compared to men in the lowest quartile. Higher estradiol levels also correlated with reduced BPH risk, and the researchers suggested this pattern may reflect lower 5-alpha reductase activity in men with higher circulating testosterone.¹⁶

How Testosterone Affects the Bladder Directly

Beyond the prostate itself, testosterone has direct effects on the bladder muscle that could help explain why some men feel better after treatment. The bladder’s smooth muscle (the detrusor) relies on a balance between contraction and relaxation. Lab studies show that testosterone at physiological concentrations activates a specific type of potassium channel in bladder smooth muscle cells, decreasing excitability and promoting relaxation.¹⁷ This effect is rapid, working through a non-genomic mechanism rather than the slow gene-transcription pathway most hormones use.

At the same time, very low testosterone appears to weaken the bladder muscle’s ability to contract when it should. In animal studies, castrated rats showed significantly weaker bladder contractions compared to intact rats, and testosterone replacement partially restored that contractile strength.¹⁸ Separate rat studies confirmed that testosterone inhibits involuntary bladder contractions, which is the kind of overactivity that causes urgency and frequency.¹⁹ The net effect looks like a Goldilocks situation: testosterone helps the bladder relax when it should be storing urine and contract properly when it is time to empty. Without enough testosterone, both functions suffer.

Combining Testosterone With Finasteride

For men who need testosterone therapy but have legitimate concerns about prostate growth, combining testosterone with a 5-alpha reductase inhibitor like finasteride offers an evidence-based option. In a randomized trial of older hypogonadal men receiving higher-than-replacement testosterone doses, testosterone alone increased prostate volume by about 11 cubic centimeters over 12 months. Adding finasteride completely prevented that prostate enlargement while preserving all of testosterone’s benefits for muscle strength, bone density, and body fat reduction. The researchers concluded that elevated DHT mediates testosterone-induced prostate enlargement but is not required for the musculoskeletal and metabolic benefits.²⁰

This combination strategy effectively splits testosterone’s effects, letting you keep the benefits in muscle, bone, and metabolism while blocking the DHT-mediated pathway that enlarges the prostate. It is worth noting that finasteride has its own side effects (including sexual side effects in some men), so this is a conversation to have with a prescriber rather than a universal recommendation.

When Testosterone Therapy Is Still Off the Table

None of this means testosterone therapy is appropriate for every man with an enlarged prostate. The Endocrine Society’s clinical practice guideline recommends against testosterone therapy in men with severe BPH symptoms, defined as an AUA/IPSS prostate symptom score above 19.²¹ The guideline also lists untreated obstructive sleep apnea, uncontrolled heart failure, and elevated red blood cell counts as contraindications. For men with mild to moderate BPH symptoms who also have documented low testosterone, the evidence is reassuring. For men whose urinary symptoms are severe enough to significantly impair quality of life, those symptoms need to be managed or reduced first.

The evidence gap worth acknowledging is in long-term safety for men with severe BPH specifically. Most trials have enrolled men with mild or absent urinary symptoms. Short-term data in men with mild BPH look favorable, but longer follow-up in men with more advanced disease is still limited.

Weight Loss, Testosterone, and Urinary Symptoms

For overweight men with low testosterone, weight loss itself raises testosterone levels. A randomized trial of overweight and obese men found that both high-protein and high-carbohydrate weight loss diets significantly increased total testosterone, free testosterone, and sex hormone binding globulin. However, lower urinary tract symptoms did not change in either group.²² So while weight loss is beneficial for testosterone levels and overall metabolic health, the testosterone increase from losing weight alone may not be enough to improve urinary symptoms. This suggests that the testosterone-urinary benefit seen in other trials may require reaching a certain threshold of testosterone levels, or that the benefit operates through mechanisms that dietary weight loss does not fully replicate.

Selective Androgen Receptor Modulators

Researchers have been working on compounds that could deliver testosterone’s benefits to muscle and bone while largely sparing the prostate. These selective androgen receptor modulators, or SARMs, are designed to activate the androgen receptor in a tissue-specific way. Nonsteroidal SARMs do not get converted to DHT by 5-alpha reductase and do not get converted to estrogen by aromatase.²³ In preclinical studies, several SARMs have increased muscle and bone mass in rodent models with varying degrees of prostate sparing.²⁴ They remain investigational compounds, and none have been approved for treating low testosterone or BPH. The SARMs currently sold online as supplements are unregulated and have uncertain purity and dosing. But the concept itself, activating androgen pathways selectively so that muscle and bone benefit while the prostate is left alone, represents where the field is heading.²⁵

Supraphysiological Testosterone and Prostate Cancer

In a development that would have baffled researchers 30 years ago, very high doses of testosterone are now being studied as a treatment for advanced prostate cancer. In lab settings, flooding castration-resistant prostate cancer cells with testosterone can actually trigger cell death and halt proliferation, the opposite of what the old model predicted.²⁶ This “testosterone paradox” appears to involve several complementary mechanisms, including direct induction of programmed cell death in cancer cells that have adapted to very low androgen environments.²⁷ Clinical trials of bipolar androgen therapy, which cycles men between supraphysiological testosterone and near-zero levels, are ongoing. This is firmly experimental and applies to a very different clinical situation than BPH, but it underscores how thoroughly the old assumptions about testosterone and the prostate have been upended.